Biomarkers of premature atherosclerosis.

[1]  D. Steinberg,et al.  Role of oxidised low density lipoprotein in atherogenesis. , 1993, British heart journal.

[2]  E. Ernst,et al.  Fibrinogen as a Cardiovascular Risk Factor , 1993, Annals of Internal Medicine.

[3]  D. Steinberg,et al.  Role of oxidized low density lipoprotein in atherogenesis. , 1991, The Journal of clinical investigation.

[4]  P. Edwards,et al.  Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. , 1995, Circulation.

[5]  A. Yeung,et al.  Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. , 1996, Circulation.

[6]  A. Folsom,et al.  Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. , 1997, Circulation.

[7]  P. Tsao,et al.  Nitric oxide regulates monocyte chemotactic protein-1. , 1997, Circulation.

[8]  R. Schwartz,et al.  Enhanced endothelin-mediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. , 1997, Circulation.

[9]  P. Groop,et al.  Hyperreactivity to nitrovasodilators in forearm vasculature is related to autonomic dysfunction in insulin-dependent diabetes mellitus. , 1997, Circulation.

[10]  J. Mehta,et al.  Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. , 1998, Journal of the American College of Cardiology.

[11]  P. Libby,et al.  Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor- deficient mice. , 1998, The Journal of clinical investigation.

[12]  R. Schmieder,et al.  Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. , 1998, Circulation.

[13]  M. Cybulsky,et al.  Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. , 1999, Circulation research.

[14]  M. Burdick,et al.  IL-8 is an angiogenic factor in human coronary atherectomy tissue. , 2000, Circulation.

[15]  F. Parhami,et al.  Tumor Necrosis Factor-&agr; Promotes In Vitro Calcification of Vascular Cells via the cAMP Pathway , 2000, Circulation.

[16]  R. D'Agostino,et al.  Association of Fibrinogen With Cardiovascular Risk Factors and Cardiovascular Disease in the Framingham Offspring Population , 2000, Circulation.

[17]  C. Stefanadis,et al.  The Impact of Risk Factors for Atherosclerosis on the Vasomotor Effects of Inhibition of Nitric Oxide Synthesis in Patients with Normal Angiograms , 2000, Cardiology.

[18]  G. Lowe,et al.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. , 2000, The New England journal of medicine.

[19]  S. Haffner,et al.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.

[20]  D. Wagner,et al.  Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice. , 2000, Circulation.

[21]  J. Cutler,et al.  Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. , 2000, Circulation.

[22]  S. Humphries,et al.  Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? , 2000, Atherosclerosis.

[23]  C. Ihling,et al.  Coexpression of Endothelin-Converting Enzyme-1 and Endothelin-1 in Different Stages of Human Atherosclerosis , 2001, Circulation.

[24]  I. Holme,et al.  High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study , 2001, The Lancet.

[25]  D. Tousoulis,et al.  Vascular cell adhesion molecule‐1 and intercellular adhesion molecule‐1 serum level in patients with chest pain and normal coronary arteries (syndrome X) , 2001, Clinical cardiology.

[26]  J. Danesh,et al.  Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis , 2001, The Lancet.

[27]  M. Cybulsky,et al.  A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. , 2001, The Journal of clinical investigation.

[28]  W. Kisiel,et al.  Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. , 2001, The Journal of clinical investigation.

[29]  Per Magne Ueland,et al.  Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. , 2002, JAMA.

[30]  A. Daugherty,et al.  Interleukin-18 Enhances Atherosclerosis in Apolipoprotein E 2 / 2 Mice Through Release of Interferon-g , 2002 .

[31]  J. Ruidavets,et al.  Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers. , 2002, Diabetes care.

[32]  Nancy R Cook,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. , 2002, The New England journal of medicine.

[33]  P. Murphy.  International Union of Pharmacology. XXX. Update on Chemokine Receptor Nomenclature , 2002, Pharmacological Reviews.

[34]  Ose,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .

[35]  A. Daugherty,et al.  Interleukin-18 Enhances Atherosclerosis in Apolipoprotein E−/− Mice Through Release of Interferon-&ggr; , 2002, Circulation research.

[36]  C. Tsioufis,et al.  Effects of combined administration of vitamins C and E on reactive hyperemia and inflammatory process in chronic smokers. , 2003, Atherosclerosis.

[37]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[38]  Sidney C. Smith,et al.  MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .

[39]  K. Rockett,et al.  Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. , 2003, The Journal of clinical investigation.

[40]  S. Rubin,et al.  Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). , 2003, The American journal of cardiology.

[41]  D. Hume,et al.  CSF-1 as a regulator of macrophage activation and immune responses. , 2003, Archivum immunologiae et therapiae experimentalis.

[42]  M. Aydın,et al.  Levels of serum IL-1beta, IL-2, IL-8 and tumor necrosis factor-alpha in patients with unstable angina pectoris. , 2003, Mediators of inflammation.

[43]  D. Freimark,et al.  Association of elevated homocysteine levels with a higher risk of recurrent coronary events and mortality in patients with acute myocardial infarction. , 2003, Archives of internal medicine.

[44]  C. Meisinger,et al.  C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score: Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany , 2004, Circulation.

[45]  H. Drexler,et al.  Endothelial function: a critical determinant in atherosclerosis? , 2004, Circulation.

[46]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[47]  J. Keaney,et al.  Role of oxidative modifications in atherosclerosis. , 2004, Physiological reviews.

[48]  L. Rabbani,et al.  Circulating Levels of IL-1β, a Prothrombotic Cytokine, are Elevated in Unstable Angina Versus Stable Angina , 2000, Journal of Thrombosis and Thrombolysis.

[49]  Heejung Bang,et al.  Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study , 2004, Circulation.

[50]  P. Ganz,et al.  Role of Endothelial Dysfunction in Atherosclerosis , 2004, Circulation.

[51]  M. Laakso,et al.  Elevated Plasma Homocysteine Level Is an Independent Predictor of Coronary Heart Disease Events in Patients with Type 2 Diabetes Mellitus , 2004, Annals of Internal Medicine.

[52]  S. Neubauer,et al.  High‐resolution, multicontrast three‐dimensional‐MRI characterizes atherosclerotic plaque composition in ApoE–/– mice ex vivo , 2004, Journal of Magnetic Resonance Imaging.

[53]  A. Hofman,et al.  Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic Stroke: The Rotterdam Study , 2005, Circulation.

[54]  J. Keaney.  Oxidative stress and the vascular wall: NADPH oxidases take center stage. , 2005, Circulation.

[55]  J. Strong,et al.  Elevated Serum C-Reactive Protein Levels and Advanced Atherosclerosis in Youth , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[56]  U. Singh,et al.  Vitamin E, oxidative stress, and inflammation. , 2005, Annual review of nutrition.

[57]  H Tunstall-Pedoe,et al.  Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. , 2005, JAMA.

[58]  J. Polak,et al.  C-Reactive Protein and the 10-Year Incidence of Coronary Heart Disease in Older Men and Women: The Cardiovascular Health Study , 2005, Circulation.

[59]  C. Stefanadis,et al.  Asymmetrical dimethylarginine regulates endothelial function in methionine-induced but not in chronic homocystinemia in humans: effect of oxidative stress and proinflammatory cytokines. , 2006, The American journal of clinical nutrition.

[60]  P. Vanhoutte,et al.  Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). , 2006, American journal of physiology. Heart and circulatory physiology.

[61]  P. Vanhoutte,et al.  Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). , 2006, American journal of physiology. Heart and circulatory physiology.

[62]  C. Dinarello.  Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. , 2006, The American journal of clinical nutrition.

[63]  E. Stranden,et al.  Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease , 2006, Vascular medicine.

[64]  Z. Varghese,et al.  Mechanisms of Dysregulation of Low-Density Lipoprotein Receptor Expression in Vascular Smooth Muscle Cells by Inflammatory Cytokines , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[65]  Weibin Shi,et al.  Effect of Aging on Fatty Streak Formation in a Diet-Induced Mouse Model of Atherosclerosis , 2007, Journal of Vascular Research.

[66]  B. Nordestgaard,et al.  Improving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B: The Copenhagen City Heart Study , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[67]  C. Stefanadis,et al.  Cold pressor test as a marker for the detection of early stage coronary atherosclerosis. , 2007, International journal of cardiology.

[68]  H. Markus,et al.  High-Sensitivity C-Reactive Protein Is Not Associated With Carotid Intima-Media Progression: The Carotid Atherosclerosis Progression Study , 2007, Stroke.

[69]  P. Libby,et al.  Mast cells promote atherosclerosis by releasing proinflammatory cytokines , 2007, Nature Medicine.

[70]  R. D'Agostino,et al.  Association of multiple inflammatory markers with carotid intimal medial thickness and stenosis (from the Framingham Heart Study). , 2007, The American journal of cardiology.

[71]  M. Simoons,et al.  Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial , 2007, Heart.

[72]  N. Tamaki,et al.  Plasma Interleukin-6 and Tumor Necrosis Factor-α Can Predict Coronary Endothelial Dysfunction in Hypertensive Patients , 2007, Hypertension Research.

[73]  H. Jakubowski.  The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease. , 2008, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[74]  [Role of biochemical risk factors and markers for the risk of atherosclerosis]. , 2008, Recenti progressi in medicina.

[75]  J. Romijn,et al.  Elevated CRP levels are associated with increased carotid atherosclerosis independent of visceral obesity. , 2008, Atherosclerosis.

[76]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[77]  S. Virani,et al.  Novel markers of inflammation in atherosclerosis , 2008, Current atherosclerosis reports.

[78]  A. Peters,et al.  Common genetic polymorphisms and haplotypes of fibrinogen alpha, beta, and gamma chains affect fibrinogen levels and the response to proinflammatory stimulation in myocardial infarction survivors: the AIRGENE study. , 2008, Journal of the American College of Cardiology.

[79]  Donald Metcalf,et al.  Hematopoietic cytokines. , 2008, Blood.

[80]  G. L. Salvagno,et al.  Il ruolo del laboratorio clinico nella valutazione di fattori e marcatori di rischio aterosclerotico , 2008 .

[81]  M. Bo,et al.  High-Sensitivity C-Reactive Protein Is Not Independently Associated With Peripheral Subclinical Atherosclerosis , 2009, Angiology.

[82]  M. Rizzo,et al.  Markers of inflammation are strong predictors of subclinical and clinical atherosclerosis in women with hypertension , 2009, Coronary artery disease.

[83]  M. Benn.  Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. , 2009, Atherosclerosis.

[84]  Lan Huang,et al.  C-reactive Protein Upregulates Receptor for Advanced Glycation End Products Expression and Alters Antioxidant Defenses in Rat Endothelial Progenitor Cells , 2009, Journal of cardiovascular pharmacology.

[85]  Gary Shaw,et al.  Interleukin-1 Regulates Multiple Atherogenic Mechanisms in Response to Fat Feeding , 2009, PloS one.

[86]  Børge G Nordestgaard,et al.  Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial , 2009, The Lancet.

[87]  B. Blackman,et al.  Human IL-8 Regulates Smooth Muscle Cell VCAM-1 Expression in Response to Endothelial Cells Exposed to Atheroprone Flow , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[88]  G. Moneta,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[89]  Qingbo Xu,et al.  Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. , 2008, European heart journal.